The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun)
Drug Channels
This week, we're rerunning some popular posts while we prepare for Friday's live video webinar: PBM Industry Update 2026: Trends, Challenges, and What's Ahead .
pharminent
April 6, 2026 (Last updated: April 6, 2026)
Drug Channels
This week, we’re rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead .
